Lewis Barry Silverman, M.D.
Co-Author
This page shows the publications co-authored by Lewis Silverman and Andrew Place.
Connection Strength
3.082
-
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 07; 65(7):e27062.
Score: 0.754
-
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec; 16(16):1677-90.
Score: 0.639
-
Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022 Apr; 69(4):e29542.
Score: 0.245
-
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 11 01; 39(31):3496-3505.
Score: 0.236
-
Corrigendum. Pediatr Blood Cancer. 2021 Mar; 68(3):e28885.
Score: 0.228
-
Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 01; 68(1):e28719.
Score: 0.225
-
A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer. Pediatr Blood Cancer. 2019 04; 66(4):e27568.
Score: 0.198
-
Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv. 2018 06 26; 2(12):1449-1458.
Score: 0.192
-
Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. Br J Haematol. 2022 Mar 21.
Score: 0.062
-
Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. Blood Adv. 2022 01 11; 6(1):72-81.
Score: 0.061
-
Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood. 2021 05 06; 137(18):2463-2480.
Score: 0.058
-
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 06; 11(6):1424-1439.
Score: 0.057
-
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2017 Feb 15; 23(4):1012-1024.
Score: 0.043
-
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
Score: 0.042
-
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
Score: 0.041
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.